MY107433A - Modiefied biological material. - Google Patents

Modiefied biological material.

Info

Publication number
MY107433A
MY107433A MYPI90001781A MYPI19901781A MY107433A MY 107433 A MY107433 A MY 107433A MY PI90001781 A MYPI90001781 A MY PI90001781A MY PI19901781 A MYPI19901781 A MY PI19901781A MY 107433 A MY107433 A MY 107433A
Authority
MY
Malaysia
Prior art keywords
species
rejection
complement
modiefied
biological material
Prior art date
Application number
MYPI90001781A
Other languages
English (en)
Inventor
Frederick Williams Alan
James Graham White David
Original Assignee
Imutran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY107433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898922987A external-priority patent/GB8922987D0/en
Priority claimed from GB909017198A external-priority patent/GB9017198D0/en
Application filed by Imutran Ltd filed Critical Imutran Ltd
Publication of MY107433A publication Critical patent/MY107433A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
MYPI90001781A 1989-10-12 1990-10-12 Modiefied biological material. MY107433A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898922987A GB8922987D0 (en) 1989-10-12 1989-10-12 Modified biological material
GB909017198A GB9017198D0 (en) 1990-08-06 1990-08-06 Modified biological material

Publications (1)

Publication Number Publication Date
MY107433A true MY107433A (en) 1995-12-30

Family

ID=26296038

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001781A MY107433A (en) 1989-10-12 1990-10-12 Modiefied biological material.

Country Status (27)

Country Link
US (1) US6495735B1 (enExample)
EP (2) EP0495852B1 (enExample)
JP (1) JP3302358B2 (enExample)
KR (2) KR920702410A (enExample)
CN (2) CN1122719C (enExample)
AT (1) ATE139562T1 (enExample)
AU (1) AU654116B2 (enExample)
BG (1) BG61080B1 (enExample)
CA (1) CA2067235A1 (enExample)
CY (1) CY1996A (enExample)
DE (2) DE495852T1 (enExample)
DK (1) DK0495852T3 (enExample)
ES (1) ES2060561T3 (enExample)
FI (1) FI921618L (enExample)
GR (2) GR940300004T1 (enExample)
HK (1) HK48497A (enExample)
HU (1) HUT64584A (enExample)
IE (1) IE75345B1 (enExample)
IL (2) IL95970A0 (enExample)
IN (1) IN171948B (enExample)
MY (1) MY107433A (enExample)
NO (2) NO303502B1 (enExample)
NZ (2) NZ235657A (enExample)
PT (2) PT95580B (enExample)
RO (1) RO109863B1 (enExample)
SG (1) SG72614A1 (enExample)
WO (1) WO1991005855A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
JP2750220B2 (ja) * 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
CA2082277A1 (en) * 1990-05-11 1991-11-12 Damien F. J. Purcell Cd46 variants
US5846715A (en) * 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
WO1993002188A1 (en) * 1991-07-15 1993-02-04 Oklahoma Medical Research Foundation Universal donor cells
US6916654B1 (en) * 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
FI951325A7 (fi) * 1992-09-22 1995-05-09 Nextran Proteiinien kuljetus membraanien välisellä siirrolla ksenogeenisten el insiirrännäisten esisovittamista varten ja muihin tarkoituksiin
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP0773993A4 (en) * 1994-08-19 2000-07-05 Gen Hospital Corp PORCINE CELLS TREATED BY GENETIC ENGINEERING
CA2227584A1 (en) * 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
WO1997035886A1 (en) * 1996-03-22 1997-10-02 Imutran Limited Surfaces which prevent or reduce complement activation
US6423316B1 (en) 1997-03-26 2002-07-23 Imperial College Innovative Limited Anticoagulant fusion protein anchored to cell membrane
US6825395B1 (en) 1997-07-14 2004-11-30 Nippon Meat Packers, Inc. Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55)
US7419683B2 (en) * 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
WO2005009134A1 (en) 2003-07-21 2005-02-03 Lifecell Corporation ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE
KR20120050485A (ko) 2009-08-14 2012-05-18 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
JP6327855B2 (ja) 2010-09-03 2018-05-23 アッヴィ・ステムセントルクス・エル・エル・シー 新規モジュレータ及びその使用法
CN103492576A (zh) 2011-02-14 2014-01-01 雷维维科公司 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪
EP3799893A1 (en) 2013-11-04 2021-04-07 LifeCell Corporation Methods of removing alpha-galactose
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081570A4 (en) * 1981-06-12 1985-09-02 Univ Ohio GENETIC TRANSFORMATION OF ZYGOTS.
US4431636A (en) 1982-05-24 1984-02-14 American Cyanamid Company Bis(4-O-polyhexaose-thio)-phenyl ureas and method of use
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
JPS62104594A (ja) * 1985-10-31 1987-05-15 Terumo Corp クエン酸塩利用能検査用培地組成物
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59

Also Published As

Publication number Publication date
NO303502B1 (no) 1998-07-20
HU9201240D0 (en) 1992-06-29
ES2060561T3 (es) 1996-08-01
NZ248153A (en) 1997-07-27
DK0495852T3 (da) 1996-07-15
FI921618A0 (fi) 1992-04-10
IE903649A1 (en) 1991-04-24
IE75345B1 (en) 1997-08-27
ATE139562T1 (de) 1996-07-15
NO921438L (no) 1992-04-10
AU654116B2 (en) 1994-10-27
NZ235657A (en) 1994-05-26
NO982131D0 (no) 1998-05-11
DE69027535T2 (de) 1996-11-28
CY1996A (en) 1997-09-05
KR100317106B1 (ko) 2001-12-22
EP0709459A2 (en) 1996-05-01
CN1491624A (zh) 2004-04-28
RO109863B1 (ro) 1995-06-30
BG96329A (bg) 1993-12-24
EP0709459A3 (en) 1999-01-07
US6495735B1 (en) 2002-12-17
CA2067235A1 (en) 1991-04-13
ES2060561T1 (es) 1994-12-01
FI921618A7 (fi) 1992-04-10
EP0495852A1 (en) 1992-07-29
DE495852T1 (de) 1994-03-31
WO1991005855A1 (en) 1991-05-02
BG61080B1 (bg) 1996-10-31
EP0495852B1 (en) 1996-06-19
HK48497A (en) 1997-04-25
JP3302358B2 (ja) 2002-07-15
AU6539290A (en) 1991-05-16
DE69027535D1 (de) 1996-07-25
KR920702410A (ko) 1992-09-04
PT101896A (pt) 1998-02-27
PT95580B (pt) 1999-05-31
HUT64584A (en) 1994-01-28
IL120795A0 (en) 1997-09-30
GR3020741T3 (en) 1996-11-30
FI921618L (fi) 1992-04-10
PT101896B (pt) 2003-01-31
NO982131L (no) 1992-04-10
IN171948B (enExample) 1993-02-13
IL95970A0 (en) 1992-05-25
NO921438D0 (no) 1992-04-10
GR940300004T1 (en) 1994-02-28
JPH05503074A (ja) 1993-05-27
PT95580A (pt) 1991-09-13
SG72614A1 (en) 2000-05-23
CN1122719C (zh) 2003-10-01
CN1051199A (zh) 1991-05-08

Similar Documents

Publication Publication Date Title
MY107433A (en) Modiefied biological material.
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
MXPA98002434A (es) Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados.
AU9058091A (en) Preparation of nucleic acid samples
DK720488D0 (da) Immunokompromitterede kimaerepattedyr og anvendelse heraf til fremstilling af celler og stoffer
ATE71298T1 (de) Immunoregulation.
PL319404A1 (en) Implanted foreign pieces for introducing active substances into plant tissue
LT2069B (lt) Alpha-arilo-4-/4,5-dihidro-3,5-diokso-1,2,4--triazino-2-(3h)-il/benzolacetonitrilu gavimo budas
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
Dye et al. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors
HUT54893A (en) Use of 5-adenosylmethionine for treating pancreatitis and for preventing rejection of transplanted pancreas
DK0410319T3 (da) Middel til spirogyrabekæmpelse og desodorisering
AU605159B2 (en) Improved mammal immunization
NZ209467A (en) Herbicidal composition derived from phomopsis cirsii and septoria cirsii
Coffaro TRANSPLANTATION IMMUNITY IN THE SEA URCHIN.
ATE279945T1 (de) Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten
Pilat et al. Hematopoietic repopulation, in vivo, with genetically defined clones derived from HOXB4 expressing ES-cells
Kuipers Combinations of antimicrobial agents: II. The in vitro sensitivity of 52 strains of proteus species to sulphafurazole, polymyxins and combinations of sulphafurazole and polymyxins
Kersten Cellular modulation of acute graft-vs.-host disease
Bertschinger [Contribution to the ethical appraisal of xenotransplantation with respect to protection of the dignity of the animals][Article in German]
Abramson et al. Experimental Frontal Bone Cranioplasty Using a Cellulose Acetate Filter Technique.
Titova et al. The mechanism of regulation of the growth of organs in embryogenesis: Communication II. The action of splenic tissue transplants from chick embryos, enlarged under the influence of adult spleen on growth of the organs of normal chick embryos
UA12061A1 (uk) Засіб для лікуваhhя цукрового діабету